Consenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quística

Máiz, Luís; Escribano, Amparo; Olveira, Casilda; Oliver, Antonio; Asensio, Òscar; Gartner, Sílvia; Romá, Eva; Quintana‐Gallego, Esther; Salcedo, Antonio; Girón, Rosa; Barrio, María Isabel; Pastor, María Dolores; Prados, Concepción; Martínez-Martínez, Maria Teresa; Barberán, José; Castón, Juan José; Martı́nez-Martı́nez, Luis; Poveda, José Luís; Gracia, Javier de; Solé, Amparó

doi:10.1016/j.arbres.2014.09.021

Cited by 36 publications

(8 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the early stages of colonization, P. aeruginosa resembles environmental isolates with typical rough colonies but later they develop a distinctive mucoid morphotype that facilitates the growth of biofilms also observed in non-mucoid strains. This modification has been linked to the persistence of P. aeruginosa and the difficulties involved in its eradication, even under antimicrobial treatment with either intravenous or inhaled antibiotics [12][13][14].…”

Section: Pseudomonas Aeruginosa Microbiology and Pathogenicitymentioning

confidence: 99%

See 1 more Smart Citation

Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases

García‐Clemente

Rosa

Máiz

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Pseudomonas aeruginosa (P. aeruginosa) is a ubiquitous and opportunistic microorganism and is considered one of the most significant pathogens that produce chronic colonization and infection of the lower respiratory tract, especially in people with chronic inflammatory airway diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and bronchiectasis. From a microbiological viewpoint, the presence and persistence of P. aeruginosa over time are characterized by adaptation within the host that precludes any rapid, devastating injury to the host. Moreover, this microorganism usually develops antibiotic resistance, which is accelerated in chronic infections especially in those situations where the frequent use of antimicrobials facilitates the selection of “hypermutator P. aeruginosa strain”. This phenomenon has been observed in people with bronchiectasis, CF, and the “exacerbator” COPD phenotype. From a clinical point of view, a chronic bronchial infection of P. aeruginosa has been related to more severity and poor prognosis in people with CF, bronchiectasis, and probably in COPD, but little is known on the effect of this microorganism infection in people with asthma. The relationship between the impact and treatment of P. aeruginosa infection in people with airway diseases emerges as an important future challenge and it is the most important objective of this review.

show abstract

Section: Pseudomonas Aeruginosa Microbiology and Pathogenicitymentioning

confidence: 99%

“…Accordingly, eradication has become the primary objective. It has been shown that 2-3 weeks of early treatment with inhaled antibiotics [91][92][93], usually in association with systemic antibiotics active against P. aeruginosa [13,94,95], achieves high rates of eradication and delays CBI.…”

Section: Transversalmentioning

confidence: 99%

Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases

García‐Clemente

Rosa

Máiz

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Culture results during the year prior to inclusion were registered and used to calculate the annual prevalence of CF pathogens. Pseudomonas aeruginosa colonization status was reported by participant clinicians following the modified Leeds criteria that have been recently adopted in the Spanish consensus guidelines [7,8].…”

Section: Data Collectionmentioning

confidence: 99%

Bronchopulmonary infection–colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study

Caballero

Campo

Royuela

et al. 2016

Journal of Cystic Fibrosis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Only the first exacerbation diagnosed and treated with antibiotics during the study period was considered. Mild exacerbations were those treated with oral antibiotics as outpatients, whereas moderate to severe exacerbations were those requiring hospitalization, intravenous therapy, intensive care admission, and/or mechanical ventilation [9].…”

Section: Methodsmentioning

confidence: 99%

Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study

Scioscia

Amaro

Alcaraz-Serrano

et al. 2019

JCM

View full text Add to dashboard Cite

Background: Bronchiectasis exacerbations are often treated with prolonged antibiotic use, even though there is limited evidence for this approach. We therefore aimed to investigate the baseline clinical and microbiological findings associated with long courses of antibiotic treatment in exacerbated bronchiectasis patients. Methods: This was a bi-centric prospective observational study of bronchiectasis exacerbated adults. We compared groups receiving short (≤14 days) and long (15–21 days) courses of antibiotic treatment. Results: We enrolled 191 patients (mean age 72 (63, 79) years; 108 (56.5%) females), of whom 132 (69%) and 59 (31%) received short and long courses of antibiotics, respectively. Multivariable logistic regression of the baseline variables showed that long-term oxygen therapy (LTOT), moderate–severe exacerbations, and microbiological isolation of Pseudomonas aeruginosa were associated with long courses of antibiotic therapy. When we excluded patients with a diagnosis of community-acquired pneumonia (n = 49), in the model we found that an etiology of P. aeruginosa remained as factor associated with longer antibiotic treatment, with a moderate and a severe FACED score and the presence of arrhythmia as comorbidity at baseline. Conclusions: Decisions about the duration of antibiotic therapy should be guided by clinical and microbiological assessments of patients with infective exacerbations.

show abstract

Consenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quística

Cited by 36 publications

References 138 publications

Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases

Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases

Bronchopulmonary infection–colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study

Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study

Contact Info

Product

Resources

About